All In Biotech

Drug Trial Radar · NCT07124013

A Study of Olomorasib (LY3537982) in Healthy Japanese Participants

An Open-Label, Phase 1 Study to Investigate the Comparability of the Pharmacokinetics of Olomorasib (LY3537982) Between Two Capsule Formulations and to Evaluate the Food Effect in Healthy Japanese Participants

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 191 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

191

Actual

Start

Sep 16, 2025

Primary completion

Jan 5, 2026

Study completion Jan 5, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Aug 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare and see how food affects the amount of olomorasib in the blood when olomorasib is taken in two different capsule forms. Participation in the study will last approximately 6 weeks.

Conditions

  • Healthy

Interventions

  • OlomorasibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of OlomorasibTime frame: Day 1 (Predose) through Day 7 (72 Hours Postdose)
  2. PK: Area under the Concentration versus Time Curve from Time Zero to Time t (AUC[0-tlast]) of OlomorasibTime frame: Day 1 (Predose) through Day 7 (72 Hours Postdose)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Souseikai Fukuoka Mirai Hospital

    Fukuoka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.